Enanta Pharmaceuticals (ENTA) Current Leases (2016 - 2026)
Enanta Pharmaceuticals posted quarterly Current Leases of $3.8 million for Q1 2026, up 71.17% year-on-year from $2.2 million in Q1 2025, and up 14.36% on a QoQ basis from $3.3 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) has 10 years of Current Leases data on file, last reported at $3.8 million in Q1 2026.
- For the quarter ending Q1 2026, Current Leases rose 71.17% year-over-year to $3.8 million; the trailing twelve-month figure through Mar 2026 stood at $3.8 million (up 71.17% YoY), and the FY2025 full-year result was $3.1 million, up 106.43% from the prior year.
- Current Leases for Q1 2026 stood at $3.8 million, up from $3.3 million in the prior quarter.
- Across five years, Current Leases topped out at $5.4 million in Q2 2023 and bottomed at $1.0 million in Q4 2024.
- The 5-year median for Current Leases is $3.1 million (2025), against an average of $3.3 million.
- The widest annual swing landed in 2024, when Current Leases plunged 79.74%; it then jumped 226.74% in 2025.
- A 5-year view of Current Leases shows it stood at $3.5 million in 2022, then soared by 42.46% to $5.0 million in 2023, then slumped by 79.74% to $1.0 million in 2024, then surged by 226.74% to $3.3 million in 2025, then rose by 14.36% to $3.8 million in 2026.
- The last three Current Leases figures came in at $3.8 million (Q1 2026), $3.3 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 83,991.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 720.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 45.66 Mn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - | 3.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.76 Mn |
| Dec 31, 2025 | 3.29 Mn |
| Sep 30, 2025 | 3.15 Mn |
| Jun 30, 2025 | 2.39 Mn |
| Mar 31, 2025 | 2.20 Mn |
| Dec 31, 2024 | 1.01 Mn |
| Sep 30, 2024 | 1.52 Mn |
| Jun 30, 2024 | 2.43 Mn |
| Mar 31, 2024 | 3.58 Mn |
| Dec 31, 2023 | 4.97 Mn |
| Sep 30, 2023 | 5.28 Mn |
| Jun 30, 2023 | 5.37 Mn |
| Mar 31, 2023 | 4.92 Mn |
| Dec 31, 2022 | 3.49 Mn |
| Sep 30, 2022 | 2.89 Mn |
| Jun 30, 2022 | 2.60 Mn |
| Mar 31, 2022 | 3.01 Mn |
| Dec 31, 2021 | 3.47 Mn |
| Sep 30, 2021 | 4.20 Mn |
| Jun 30, 2021 | 5.03 Mn |
| Mar 31, 2021 | 5.18 Mn |
| Dec 31, 2020 | 5.20 Mn |
| Sep 30, 2020 | 4.26 Mn |
| Jun 30, 2020 | 4.26 Mn |
| Mar 31, 2020 | 3.76 Mn |
| Dec 31, 2019 | 3.13 Mn |
| Sep 30, 2017 | 79,000.00 |
| Jun 30, 2017 | 75,000.00 |
| Mar 31, 2017 | 75,000.00 |
| Dec 31, 2016 | 75,000.00 |
| Sep 30, 2016 | 73,000.00 |